Announcements Trials
Browse Landscape

Phase

Phase 2 31Phase 1 5Phase 3 2Phase 1/2 2

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 1CNS 1

Conditions

Lymphoma, Non-Hodgkin 1Glioblastoma 1

Interventions

Cisplatin 726Carboplatin 609Paclitaxel 579Cyclophosphamide 516Radiotherapy 511Docetaxel 477Fluorouracil 454Gemcitabine 438Doxorubicin 383Capecitabine 362Dexamethasone 328Oxaliplatin 289pembrolizumab 283Leucovorin 283Bevacizumab 275Etoposide 272Vincristine 270Rituximab 246Prednisone 223Pemetrexed 217Cytarabine 205Drug Therapy 194Trastuzumab 176Irinotecan 174Methotrexate 171Lenalidomide 137Nivolumab 136Filgrastim 135Epirubicin 129Tamoxifen 128

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × enzastaurin × Clear all
NCT00295815 2019-09-12

Enzastaurin Versus Lomustine in Glioblastoma

Eli Lilly and Company

Phase 3 Completed
397 enrolled
CNS

Glioblastoma

NCT00332202 2018-09-10

PRELUDE:Study to Investigate the Prevention of Relapse in Lymphoma Using Daily Enzastaurin

Eli Lilly and Company

Phase 3 Completed
758 enrolled 20 charts
Lymphoid

Lymphoma, Non-Hodgkin

Data powered by HemOnc (CC BY 4.0) Colophon âš¡